Hormonal therapy in breast cancer

A model disease for the personalization of cancer care

Shannon Puhalla, Saveri Bhattacharya, Nancy E. Davidson

Research output: Contribution to journalArticle

Abstract

The treatment of breast cancer is driven by subtype classification, of which the assessment of hormone receptor status is one of the important determinants of therapy. The use of hormonal therapy to treat estrogen-receptor positive breast cancer has been studied for over a century and is one of the well-described uses of personalized medicine. In this review, we will describe the classification of hormone receptor status and the various endocrine treatment strategies. Opportunities for personalization of care are illustrated.

Original languageEnglish (US)
Pages (from-to)222-236
Number of pages15
JournalMolecular Oncology
Volume6
Issue number2
DOIs
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

Breast Neoplasms
Neoplasms
Hormones
Precision Medicine
Therapeutics
Estrogen Receptors

Keywords

  • Aromatase inhibitors
  • Breast cancer
  • Endocrine therapy
  • Estrogen receptor
  • Prognostic assays
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine

Cite this

Hormonal therapy in breast cancer : A model disease for the personalization of cancer care. / Puhalla, Shannon; Bhattacharya, Saveri; Davidson, Nancy E.

In: Molecular Oncology, Vol. 6, No. 2, 04.2012, p. 222-236.

Research output: Contribution to journalArticle

Puhalla, Shannon ; Bhattacharya, Saveri ; Davidson, Nancy E. / Hormonal therapy in breast cancer : A model disease for the personalization of cancer care. In: Molecular Oncology. 2012 ; Vol. 6, No. 2. pp. 222-236.
@article{92dc921debd94996b6d3295d5ea0bd93,
title = "Hormonal therapy in breast cancer: A model disease for the personalization of cancer care",
abstract = "The treatment of breast cancer is driven by subtype classification, of which the assessment of hormone receptor status is one of the important determinants of therapy. The use of hormonal therapy to treat estrogen-receptor positive breast cancer has been studied for over a century and is one of the well-described uses of personalized medicine. In this review, we will describe the classification of hormone receptor status and the various endocrine treatment strategies. Opportunities for personalization of care are illustrated.",
keywords = "Aromatase inhibitors, Breast cancer, Endocrine therapy, Estrogen receptor, Prognostic assays, Tamoxifen",
author = "Shannon Puhalla and Saveri Bhattacharya and Davidson, {Nancy E.}",
year = "2012",
month = "4",
doi = "10.1016/j.molonc.2012.02.003",
language = "English (US)",
volume = "6",
pages = "222--236",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Hormonal therapy in breast cancer

T2 - A model disease for the personalization of cancer care

AU - Puhalla, Shannon

AU - Bhattacharya, Saveri

AU - Davidson, Nancy E.

PY - 2012/4

Y1 - 2012/4

N2 - The treatment of breast cancer is driven by subtype classification, of which the assessment of hormone receptor status is one of the important determinants of therapy. The use of hormonal therapy to treat estrogen-receptor positive breast cancer has been studied for over a century and is one of the well-described uses of personalized medicine. In this review, we will describe the classification of hormone receptor status and the various endocrine treatment strategies. Opportunities for personalization of care are illustrated.

AB - The treatment of breast cancer is driven by subtype classification, of which the assessment of hormone receptor status is one of the important determinants of therapy. The use of hormonal therapy to treat estrogen-receptor positive breast cancer has been studied for over a century and is one of the well-described uses of personalized medicine. In this review, we will describe the classification of hormone receptor status and the various endocrine treatment strategies. Opportunities for personalization of care are illustrated.

KW - Aromatase inhibitors

KW - Breast cancer

KW - Endocrine therapy

KW - Estrogen receptor

KW - Prognostic assays

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=84860436812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860436812&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2012.02.003

DO - 10.1016/j.molonc.2012.02.003

M3 - Article

VL - 6

SP - 222

EP - 236

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 2

ER -